HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. This study investigated pharmacokinetics, pharmacodynamics, and efficacy of mHemaMax (recombinant murine IL-12), and HemaMax to increase survival after total body irradiation (TBI) in mice and rhesus monkeys, respectively, with no supportive care. In mice, m-HemaMax at an optimal 20 ng/mouse dose significantly increased percent survival and survival time when administered 24 hours after TBI between 8-9 Gy (p,0.05 Pearson's chisquare test). This survival benefit was accompanied by increases in plasma interferon-c (IFN-c) and erythropoietin levels, recovery of femoral bone hematopoiesis characterized with the presence of IL-12 receptor b2 subunit-expressing myeloid progenitors, megakaryocytes, and osteoblasts. Mitigation of jejunal radiation damage was also examined. At allometrically equivalent doses, HemaMax showed similar pharmacokinetics in rhesus monkeys compared to m-HemaMax in mice, but more robustly increased plasma IFN-c levels. HemaMax also increased plasma erythropoietin, IL-15, IL-18, and neopterin levels. At non-human primate doses pharmacologically equivalent to murine doses, HemaMax (100 ng/Kg and 250 ng/Kg) administered at 24 hours after TBI (6.7 Gy/LD 50/30 ) significantly increased percent survival of HemaMax groups compared to vehicle (p,0.05 Pearson's chi-square test). This survival benefit was accompanied by a significantly higher leukocyte (neutrophils and lymphocytes), thrombocyte, and reticulocyte counts during nadir (days 12-14) and significantly less weight loss at day 12 compared to vehicle. These findings indicate successful interspecies dose conversion and provide proof of concept that HemaMax increases survival in irradiated rhesus monkeys by promoting hematopoiesis and recovery of immune functions and possibly gastrointestinal functions, likely through a network of interactions involving dendritic cells, osteoblasts, and soluble factors such as IL-12, IFN-c, and cytoprotectant erythropoietin.
Introduction
Use of ionizing radiation or nuclear devices as weapons of terrorism is now recognized as a major public health threat. In the event of a nuclear detonation, terrorist radiological (e.g., ''dirty'') bomb, or attack on a nuclear power plant in a populated area, mass casualties will occur that will be in the need of immediate medical attention [1] . At exposures approximating 4 Gy, it is estimated that 50% of individuals will die within 60 days unless there is medical intervention [2] . The majority of deaths that occur from exposures of 2-10 Gy will result from the combined effects of immune, hematopoietic, and gastrointestinal (GI) failure, as these are the most radiosensitive tissues [1] [2] [3] . To date, there are no FDA approved therapeutic agents capable of increasing the chance for survival by simultaneously promoting or accelerating the recovery of the immune, hematopoietic and gastrointestinal compartments following radiation injury.
In the event of a radiation disaster or act of terrorism affecting a large civilian population, the goal would be to provide a potent frontline therapy that increases the chance for survival of the exposed, or potentially exposed, individuals. One of the challenges in such events is that medical care and treatments will not be available immediately following radiation exposure. It is envisioned that it will take 24 hours or more to mobilize medical teams and necessary life-saving drugs and equipment to the scene of a radiation disaster [4] .
Since medical care will not be immediately available, a medical intervention capable of increasing the chance for survival as a frontline therapy would have to be efficacious when administered at protracted time points following radiation exposure. This is indeed a challenge in that total body irradiation (TBI) causes massive apoptosis to rapidly dividing cells in radiosensitive organs, such as the peripheral blood, bone marrow, and GI tract, starting immediately after radiation exposure [1, 2] . Moreover, the chance of successfully providing life-saving treatment to the exposed individuals decreases exponentially following radiation injury. Thus, the effectiveness of providing countermeasure treatments that could alleviate damage caused by radiation decreases rapidly with time.
Given this challenge, there has been a search for radiomitigation drugs that can increase the chance for survival following radiation exposure to sensitive tissues such as the immune system, bone marrow, and GI tract Numerous cytokines proteins and small molecules,are under evaluation to to assess their respective radiomitigation potential . For example Johnson et al [5] report on a small molecule cyclin-dependent kinase inhibitor which shows radiomitigation in mice when administered 20 hours after irradiation. Protein drugs based upon the bacterial flagellin protein have been shown to be radioprotective at administration prior to radiation [6] or up to four hours post-irradiation [7] , but not at 24 hours post-irradiation [7] . Recombinant human growth hormone has been reported to confer increased survival in mice when treated for five consecutive days when administered first up to 12 hours after irradiation [8] . Reviews by Singh and Yadav [9] , Hérodin and Drouet [10] , Weiss and Landauer [11] , and Dumont et al [12] provide further information on radioprotectants and mitigants.. To date, there are no reports of any of these agents conferring increased survival at 24 hours or longer post radiation exposure, either in mice or non-human primates.
HemaMax is a recombinant human interleukin-12 (IL-12) preparation that is currently being developed for use against acute radiation syndrome in humans. Previously, we have investigated the radioprotective properties of a prototype preparation, m-HemaMax, a recombinant mouse IL-12, following intravenous administration. We found that m-HemaMax was able to dramatically increase survival in mice following exposure to lethal doses of TBI when it was administered at a single, low dose, either 24 hours before or within 1 hour after radiation exposure [13, 14] . Moreover, multilineage recovery of peripheral blood cell counts via stimulation by m-HemaMax, namely white blood cells, red blood cells and platelets, was observed in both normal and tumor-bearing mice exposed to sublethal TBI [13, 14] . In these radioprotection studies, m-HemaMax showed a remarkable ability to reconstitute the bone marrow compartment following ablation [13, 14] . Overall, these data suggested that the activity of m-HemaMax in these model systems is initiated at the level of primitive cells, likely hematopoietic and non-hematopoietic stem cells, residing in the bone marrow compartment, and that activation of these primitive cells leads to regeneration of the bone marrow compartment following radioablation or radiosuppression [13, 14] .
IL-12 is a heterodimeric cytokine, comprising both p40 and p35 subunits, that is well-known for its role in immunity [15] . In numerous reports spanning about two decades, IL-12 has been shown to have an essential role in the interaction between the innate and adaptive arms of immunity by regulating inflammatory responses, innate resistance to infection, and adaptive immunity [15] . Endogenous IL-12 is required for resistance to many pathogens and to transplantable and chemically induced tumors. The hallmark effect of IL-12 in immunity is its ability to stimulate the production of interferon-gamma (IFN-c) from natural killer (NK) cells, macrophages and T cells [15] . Further, several in vitro studies in the early-mid nineties reported that IL-12 is capable of stimulating hematopoiesis synergistically with other cytokines [16] [17] [18] [19] [20] . The hematopoiesis-promoting activity of IL-12 appears to be due to a direct action on bone marrow stem cells as these studies used highly purified progenitors or even single cells. The role of IFN-c in the hematopoietic activity of IL-12 is not clear as several studies have linked both the promotion and suppression of hematopoiesis to IFN-c [21] [22] [23] [24] [25] [26] [27] . The potent effect of IL-12 in mitigating radiation injury following exposure to lethal doses of radiation was previously unknown.
Since we previously found that m-HemaMax was highly effective when administered shortly after TBI, we attempted to utilize a more stringent model of radiation exposure to investigate the ability of m-HemaMax and HemaMax to increase survival when administered at protracted time points post radiation in mice and non-human primates (NHP), respectively. In a model of radiomitigation, where single, low doses of m-HemaMax in mice or HemaMax in NHP are administered subcutaneously at 24 hours or longer post irradiation, we now show that HemaMax can provide potent mitigation of radiation injury to multiple tissues, including the immune, bone marrow, and GI compartments, leading to significant increases in survival. These results are reported herein for both murine and NHP radiomitigation models in the complete absence of supportive care. To our knowledge, this is the first report showing potent radiomitigation effects of a therapeutic agent in mice and NHP at protracted time points post radiation, such as 24 hours or longer, following acute ionizing radiation exposure. 
Materials and Methods

Ethics Statement
m-HemaMax and HemaMax
m-HemaMax (recombinant murine IL-12) was purchased from Peprotech (Rocky Hill, NJ, USA) or provided by SBH Sciences (Natick, MA, USA) exclusively to Neumedicines. HemaMax (recombinant human IL-12) was provided by SBH Sciences (Natick, MA, USA) exclusively to Neumedicines. In the initial mouse survival studies, lyophilized m-HemaMax was dissolved in phosphate buffer saline (PBS), pH = 7.2. In all other studies, mHemaMax and HemaMax were dissolved in a proprietary formulation containing trehalose, Tween 20, and sodium phosphate, pH = 5.6 (P5.6TT). Studies in mice and rhesus monkeys utilized m-HemaMax and HemaMax, respectively. PBS was used as vehicle in the initial mouse survival studies as indicated. P5.6TT was used as vehicle in all other studies.
Mice
Mouse survival studies were carried out at either BATTS Laboratories (Northridge, CA, USA; HHS OLAW A4475-01) or the Roy E. Coats Research Laboratories (University of California, Los Angeles, CA, USA; HHS OLAW A3196-01). Mouse bone marrow isolations were carried out at BATTS Laboratories. Female C57BL/6 mice were obtained from The Jackson Laboratory (Sacramento, CA, USA), and male mice from Harlan Laboratories (Placentia, CA, USA), or were bred at the Roy E. Coats Research Laboratories (Coats mice) Coats mice are gnobiotic, and consequently,are have a lesser less radiosensitive than the Harlan mice. Differences in radiation doses in experiments using the different mice consequently differed with higher radiation amounts used in the Coats mice experiments. Coats mice exposed to radiation doses of 8.6, 8.8 and 9.0 Gy in these studies whereas Harlan mice were subjected to 8 Gy unless otherwise specified. Mouse pharmacokinetic (PK) and pharmacodynamic (PD) studies and gastrointestinal (GI) tissue isolations were carried out at LAB Research, Inc. (Laval, Québec, Canada; HHS OLAW A5525-01). Male C57BL/6 mice were obtained from Charles River Canada, Inc. (Saint-Constant, Québec, Canada). In PK/PD studies involving radiation Charles River mice were subjected to 8.6 Gy TBI (LD 100/30 ). At all study sites, mice were maintained in quarantine for at least one week. Mice used in the survival and PK/PD studies were 9 weeks to 10 weeks old and weighed approximately 20 g with no signs of disease.
Survival Studies in Mice
At day 0, TBI was carried out at a lethal dose of 8.0 Gy (Harlan mice) or 9.0 Gy (Coats mice) -doses that are expected to cause death in about 90% of animals within 30 days-using GammacellH 40 with 137 Cs source (Theratronics, Ontario Canada with a rate of 71 cGy/min in Coats mice studies and 85 cGy/min in the Harlan mice studies) in a specially constructed ''pie-box'' designed to keep mice in the center of the irradiator for even distribution of radiation. Mice received subcutaneous injections of either vehicle or m-HemaMax at the indicated doses at 24 hours, 48 hours, and/or 72 hours after irradiation. Mice were monitored for survival up to day 30. During this period, mice were deprived of all supportive care, including antibiotics, to increase the stringency of the survival protocol. The mice had access to food and acidified water ad libitum.
Radiation dose dependency of the m-HemaMax effect was evaluated in mice (n = 10 per group; Coats mice), which were irradiated at lethal doses of 8.6 Gy, 8.8 Gy, and 9.0 Gy, which resulted in LD 70/30 , LD 90/30 , and LD 100/30 , respectively. Animals received vehicle or m-HemaMax at a dose of 20 ng/mouse 24 hours after TBI. Mice were monitored for survival up to day 30. No supportive care, including antibiotics, was allowed during this period. The mice had access to food and acidified water ad libitum.
Plasma PK and PD of m-HemaMax in Irradiated and NonIrradiated Mice
Mice (n = 3 per group) received m-HemaMax subcutaneously at a dose of 10 ng/mouse, 20 ng/mouse, 40 ng/mouse, or 200 ng/ mouse either in the absence of irradiation or 24 hours after an LD 100/30 (8.6 Gy; Charles River mice) of TBI. Two additional control groups of animals (n = 3 per group), which did not receive m-HemaMax, were either not exposed to radiation or irradiated at 8.6 Gy. The concentrations of m-HemaMax and IFN-c were determined in plasma from blood samples withdrawn at 45 minutes and 1.5, 3, 6, 12, 24, 48 and 72 hours after mHemaMax administration by enzyme-linked immunosorbent assay (ELISA). Plasma erythropoietin (EPO) levels were measured only at the 12 hour timepoint because of limited sample availability.
Bone Marrow and GI Histopathology in Mice
For bone marrow histopathology studies, mice (n = 2 per group) were subjected to TBI at 8.0 Gy (Harlan mice, ,LD 40/30 in this experiment) and were subsequently administered either vehicle (P5.6TT) or m-HemaMax (20 ng/mouse) subcutaneously at either (a) 24 hours, (b) 24 hours and 2 days, (c) 24 hours and 3 days, (d) 24 hours and 4 days, or (e) 24 hours and 5 days after irradiation. An additional group of mice (n = 2) received HemaMax at 24 hours after TBI. Mice were sacrificed 12 days after irradiation, and femoral bone marrow was provided as paraffin-embedded, sectioned tissues by Cyto-Pathology Diagnostic Center, Inc (Duarte, CA, USA).
For GI histopathology studies, mice (n = 3 per group) received vehicle (P5.6TT) or m-HemaMax subcutaneously at doses from 10 ng/mouse to 200 ng/mouse either in the absence of irradiation or 24 hours after a TBI at 8.6 Gy (Charles River mice, LD 100/30 ). Mice were sacrificed 3 days after irradiation, and jejunum was provided as paraffin-embedded, sectioned tissues by Cytopathology Diagnostics Center, Inc. (Duarte, CA, USA).
Sectioned tissues were deparaffinized with xylene, rehydrated with decreasing concentrations of ethanol, and subjected to the heat-induced epitope retrieval (HIER) to recover antigens. Endogenous peroxidase was inhibited with 0.3% H 2 O 2 , and background staining was blocked with the Background Sniper (Biocare Medical, LLC.; Concord, CA).
In the bone marrow histopathology studies, tissue sections were incubated with either rabbit anti-mouse IL-12 receptor beta 2 subunit (IL-12Rb2) (Sigma; St Louis, MO), rabbit anti-mouse osteocalcin (Millipore; Billerica, MA), a marker of osteoblasts, or rabbit anti-mouse Sca-1 (Epitomics; Burlingame, CA), a marker of hematopoietic stem cells. In the GI histopathology studies, tissue sections were incubated with rabbit anti-mouse IL-12Rb2, or rabbit anti-mouse leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5), a GI stem cell marker that is expressed upon GI injury. After removing the primary antibodies, tissue sections were incubated with peroxidase conjugated anti-rabbit IgG (ImmPRESS; Vector Laboratories; Burlingame, CA 
Non-Human Primates (NHP)
Male rhesus monkeys, Macaca mulatta, were purchased from Worldwide Primates, Inc., (Miami, FL, USA). Animals of 3 to 4 years of age weighing 3.5 to 5.8 Kg were acclimatized for at least 7 weeks. All rhesus monkeys included in the experiments were in good health by physical examination, were negative for Herpes Bvirus, simian immunodeficiency virus, simian T-lymphotropic virus, and simian type retrovirus, and were vaccinated against hepatitis A and measles. Animals were housed individually in stainless steel monkey cages equipped with automatic watering systems. The animal room environment was continuously controlled for temperature (2163uC), humidity (30% to 70%), light cycle (12 hours light:12 hours dark), and air change (10 to 15 air changes/hour). A standard certified commercial primate chow was available to each monkey twice a day. Food was withdrawn overnight prior to irradiation and necropsy. Animals were acclimated to the various procedures with positive reinforcement prior to study initiation. Health status was extensively evaluated to ensure animals were in good condition for the studies. All animals were provided prophylactic analgesia (buprenorphine) from day 5 to study completion. Specific euthanasia criteria were included in each experimental protocol to minimize suffering. Continuous clinical care (24 hours/7 days) were provided throughout the study to ensure prompt intervention when needed. A team of technicians and veterinarians trained in NHP medicine was responsible for clinical monitoring and provided state-of-the-art medical care.
Allometric Dose Conversion From Mice to Rhesus Monkey
m-HemaMax doses that were found effective against lethal TBI in mice were converted to their equivalent doses in rhesus monkey based on body surface area [28] . Pharmacological equivalency of the species-specific equivalent doses were evaluated in relation to the HemaMax stimulation of IFN-c secretion from peripheral blood mononuclear cells (PBMC) in vitro and the PK and PD characteristics of HemaMax in vivo.
Isolation of CD14-PBMC and Quantification of IFN-c Secretion
Human PBMC collected by apheresis were purchased from AllCells (Emeryville, CA, USA). Mouse and rhesus monkey PBMC were from Bioreclamation (Liverpool, NY, USA). CD14-PBMC were isolated as follows. Red blood cells were removed from human PBMC by a single step gradient with Ficoll-Hypaque premium (Density = 1.077; GE Healthcare Lifesciences; Piscataway, NJ, USA) and from rhesus monkey and mouse PBMC by lysis using ACK lysis buffer (Invitrogen; Carlsbad, CA, USA). To remove IL-12-secreting endogenous monocyte populations, human and rhesus monkey PBMCs were labeled with mouse antihuman CD14PE antibody (AbD Serotec; Raleigh, NC, USA), and mouse PBMCs were labeled with mouse anti-mouse CD14PE (AbD Serotec; Raleigh, NC, USA). The excess antibody was removed and cells were incubated with magnetic beads conjugated with anti-PE antibody (Miltenyi Biotec; Auburn, CA, USA). After removing the excess antibody, CD14+ cells were captured by adsorption to an LD column (Miltenyi Biotec; Auburn, CA, USA) immobilized in a magnetic field (Quadro MACSH; Miltenyi Biotec; Auburn, CA, USA). CD14-cells in the flow-through were collected, and those from humans were resuspended at a density of 14610 6 cells/mL in cold fetal bovine serum (FBS) containing 20% dimethyl sulfoxide whereas those from rhesus monkey and mouse were resuspended at a density of 2.14610 6 
IL-12Rb2 Expression in NHP and Human Bone Marrow and Small Intestine
Paraffin-embedded, sectioned tissues from NHP and human femoral bone marrow and jejunum/ileum were obtained from Biomax, Inc (Rockville, MD). NHP and human tissue sections were immunohistochemically stained for IL-12Rb2 using rabbit anti-human IL-12Rb2 according to the procedures described in the section for mice histopathology studies.
Survival Studies in NHP
At day 0, rhesus monkeys acclimated to the restraining procedure with positive reinforcement were subjected to TBI at an LD 50/30 of 6.7 Gy. Irradiation was performed in two half-dose fractions (anteroposterior and posteroanterior) at the rate of 55 cGy/minute using a Cobalt-60 unit (Theratron 780; Theratronics; Ontario, Canada). The irradiation dose was monitored with 2 dosimeters (Thermoluminescent or NanoDot dosimeters; Landauer Inc.; Glenwood, IL, USA) placed at the apex of the sternum and at the corresponding level in the interscapular area of each animal. Following TBI, animals were randomly assigned to receive subcutaneously either During the study, blood transfusions or antibiotic use was prohibited. Evidence of pain or discomfort was treated with intramuscular buprenorphine (0.01 mg/Kg to 0.05 mg/Kg at least every 8 hours). Nutritive support (e.g. liquid diets) was provided if animals presented with decreased appetite. Throughout the study, clinical signs were monitored at least twice a day, and complete blood counts and body weight were monitored once every other day. Hematology samples were analyzed with an automated hematology analyzer (Advia 120; Bayer Diagnostics; Tarrytown, NY, USA). During the study, animals were euthanized if they had respiratory distress, anorexia/decreased appetite (complete anorexia for 3 days), weight loss (in excess of 20% of baseline body weight in 72 hours), unresponsiveness to touch, acute gross blood loss, generalized seizure, or abnormal vital signs. The euthanized animals or those found dead were subjected to a full macroscopic necropsy examination, including bacteriology testing. All animals were euthanized at the end of the study on day 31.
Quantification of m-HemaMax and HemaMax and their Biomarkers in Plasma
Blood samples from mice and rhesus monkeys were collected into tubes containing ethylenediaminetetraacetic acid and were kept on ice (,30 minutes) until centrifugation. Samples were centrifuged at 15006 g for 10 minutes at 4uC. Plasma was aliquoted and stored at 270uC until use. Plasma m-HemaMax, HemaMax, and their potential biomarkers were assayed by ELISA. The ELISA kits for mouse IL-12 (p70) and IFN-c were obtained from BioLegend (San Diego, CA, USA), for NHP IL-12 from BioLegend (San Diego, CA, USA), MabTech (Mariemont, OH, USA), and R&D Systems (Minneapolis, MN, USA), for NHP IFN-c from MabTech (Mariemont, OH, USA), for human EPO, IL-18, and IL-15 from R&D Systems (Minneapolis, MN, USA), and for Neopterin from GenWay (San Diego, CA, USA). All assays were carried out in triplicate according to the manufacturers' instructions except those for NHP IL-12 in which an in-house reference standard was used instead of the standard provided by the manufacturer.
Statistical Analyses
Data were presented as mean 6 standard error (SE). Betweengroup differences in survival were evaluated with Kaplan-Meier survival analysis, followed by the Mantel-Cox Test for survival time and Pearson's chi-square test for percentage of survival. Between-group differences in blood cell counts were evaluated by analysis of variance (ANOVA), except for the number of platelet counts dropping below the transfusion level of 20,000 platelets/ml, which was analyzed by Pearson's chi-square test. Between group differences in clinical signs were evaluated by ANOVA. A P value of ,.05 was defined as the level of statistical significance.
Results
Single, Low Doses of m-HemaMax Administered 24 Hours Post TBI Increased Survival in Irradiated Mice
In the initial studies, 87.5% of mice receiving a subcutaneous ostensible dose of 100 ng/mouse of m-HemaMax at 24 hours and 72 hours post 8 Gy TBI survived for up to 30 days, whereas only 14% of vehicle mice survived this same lethal 8 Gy TBI by day 30 (P,0.005) (Figure 1a ). The actual m-HemaMax dose delivered in these studies was 10 ng/mouse (see below for a discussion concerning dose delivery). Subsequent studies evaluated whether a single dose of m-HemaMax was sufficient to provide similar radiomitigation effect. In these studies, a single, ostensible dose of m-HemaMax (300 ng/mouse; the actual delivered dose was 20-30 ng/mouse; see below for a discussion concerning dose delivery) significantly increased survival time when administered at either 24 hours (P = .001), 48 hours (P = .02), or 72 hours (P,.03 ) after a The exposure to m-HemaMax (area under the curve last; AUC last ) increased dose proportionally from 10 ng/mouse to 40 ng/mouse regardless of the presence or absence of irradiation ( Figure 3 and Table 1 ). Interestingly, maximum plasma concentrations (C max ) of m-HemaMax were consistently higher in irradiated mice as compared to non-irradiated mice at all doses ( Figure 3) . The exposure to m-HemaMax (AUC last ) at the dose of 200 ng/mouse was disproportionately higher than those at the lower doses (10 ng/mouse to 40 ng/mouse), suggesting that PK properties of m-HemaMax are non-linear at the higher dose ranges (Table 1 ). In the dose range of 10 ng/mouse to 40 ng/mouse, m-HemaMax reached C max in 3 hours to 6 hours and was eliminated with a half-life of approximately 4 hours ( Table 1) . m-HemaMax administration increased plasma IFN-c concentration with a lag time at all study doses (Figure 3 ). Of significance, IFN-c production was not abrogated in irradiated mice (Figure 3 ). In fact, for all m-HemaMax doses, except the optimal dose of 20 ng/mouse dose, plasma IFN-c levels were higher in irradiated mice compared to non-irradiated mice (Figure 3) . The exposure to IFN-c dose proportionally increased as a function of increasing mHemaMax dose from 10 ng/mouse to 200 ng/mouse (data not shown). Importantly, IFN-c was not detected in plasma of mice, which did not receive m-HemaMax regardless of the presence or absence of irradiation.
Since preliminary studies had shown that co-administration of m-HemaMax and EPO in a certain regimen led to a substantial increase in survival following lethal radiation exposure (data not shown), we sought to assess whether m-HemaMax may affect plasma levels of EPO in irradiated and non-irradiated mice. Because of the limited sample availability, plasma EPO levels could be measured in only 1 early timepoint, 12 hours after mHemaMax administration (Figure 4) . In non-irradiated, untreated animals, EPO was detectable in plasma at low pg/mL range ( Figure 4 ). Irradiation increased plasma EPO levels nearly linearly up to 80 hours post TBI, suggesting that EPO is a part of the physiological response to radiation injury (data not shown). Remarkably, however, at the optimal dose of 20 ng/mouse at 12 hours post administration (36 hours post radiation exposure), m-HemaMax substantially increased plasma EPO concentrations over the radiation-induced levels (Figure 4 ), indicating that mHemaMax potentiates the EPO-mediated physiological response to radiation, but only at or near the optimal dosing level. It is noteworthy that, at this optimal dose, plasma EPO levels were also increased in non-irradiated mice (Figure 4) . It remains to be further evaluated as to whether the EPO response to m-HemaMax administration occurs at a narrow window of m-HemaMax dose range because a highly potentiated EPO response was observed only after administration of the 20 ng/mouse dose ( Figure 4) . It is interesting to note that the IFN-c response appeared to be subdued at the 20 ng/mouse dose of m-HemaMax, the dose at which EPO was upregulated by m-HemaMax, as compared to the other doses assessed. In a mice model of multiple sclerosis, administration of EPO was reported to downregulate the inflammatory response, and in particular, suppress IFN-c [29] . Thus, these findings suggest that the increased plasma EPO levels may play a role in the suppression of plasma IFN-c levels in irradiated mice that received m-HemaMax at the dose of 20 ng/ mouse (Figure 3b ), leading to a decrease in the inflammatory response to radiation.
Other biomarkers of m-HemaMax administration were also screened, namely tumor necrosis factor-alpha (TNF-a and stem cell factor (SCF), but the plasma levels for these factors were found to be below the limit of quantitation. Femoral bone marrow from irradiated mice treated with vehicle or m-HemaMax $24 hours after TBI (LD 30/30 ) were stained for IL-12Rb2 and evaluated for histological signs of recovery from radiation-induced injury at 12 days post TBI. As a control, bone marrow from non-irradiated, untreated mice was characterized with the presence of IL-12Rb2-expressing hematopoietic stem cells, identified by co-staining for Sca-1 (a murine stem cell marker; see below), immature megakaryocytes with lobulated nuclei surrounded by a narrow rim of cytoplasm, matured megakaryocytes with lobulated nuclei and voluminous cytoplasm, and myeloid progenitor cells in the metamyelocyte stage (Figure 5a ).
Bone marrow from mice treated only with vehicle and subjected to an LD 30/30 of TBI (8.0 Gy) was characterized with minimal signs of hematopoietic regeneration and the complete lack of IL12Rb2-expressing cells after 12 days following irradiation (Figure 5b ). In contrast, mice treated with various dosing regimens of m-HemaMax showed varying levels of hematopoietic reconstitution, which was characterized with the presence of IL-12Rb2-expressing myeloid progenitors, megakaryocytes, and osteoblasts (Figure 5c-f ). Mice treated with HemaMax, which has been demonstrated to not cross react with the murine IL-12 receptor, showed some signs of regeneration, however, lacked megakaryocytes (Figure 5g ). For mice treated with HemaMax, however, no increase in the survival was observed, as compared with the vehicle control group (data not shown).
In order to further evaluate as to whether morphologically identified cells were indeed hematopoietic stem cells and osteoblasts, bone marrow tissue sections were stained for the corresponding markers, respectively, Sca-1 and osteocalcin. As depicted in Figure 6 a and b, IL-12Rb2 expression was observed on cells that were morphologically identified as hematopoietic stem cells and osteoblasts, which expressed Sca-1 and osteocalcin, respectively. Co-expression of IL-12Rb2 and Sca-1 in bone marrow tissue sections was also evaluated by a dual staining approach. As depicted in Figure 6c , a discrete subset of hematopoietic stem cells were co-stained for the presence of both IL-12Rb2 and Sca-1. Both immature and mature megakaryocytes expressing IL-12Rb2 was also evident in the bone marrow tissue sections (Figure 6c ). These findings suggest a direct role for IL-12 signaling pathway in hematopoietic reconstitution.
Similar to hematopoietic stem cells and osteoblasts in femoral bone marrow, mice jejunal crypts expressed IL-12Rb2 (Figure 7a ). In the absence of irradiation, m-HemaMax administration at doses up to 200 ng/mouse did not cause injury in jejunal crypts (Figure 7b, upper panel) . Exposure to TBI (8.6 Gy), however, resulted in substantial jejunal damage 3 days after irradiation, as evidenced by the widespread expression of LGR5, a GI stem cell marker shown to be expressed upon chemotherapy-induced GI injury [30] [31] [32] . Remarkably, administration of m-HemaMax at the low dose range of 10 ng/mouse to 40 ng/mouse dosedependently mitigated radiation-induced jejunal damage, with no LGR5 expression evident at the optimal, efficacious dose of 20 ng/mouse (Figure 7b, lower panel) . On the other hand, mHemaMax at the high dose of 200 ng/mouse exacerbated jejunal injury (Figure 7b, lower panel) . As observed with the m-HemaMax dose ranges for optimal increases in survival, these data point to a window of opportunity for mitigation of radiation injury by mHemaMax in a very low dose range of the drug that is also effective in alleviating bone marrow damage.
Allometric Dose Conversion From Mice to NHP
In order to achieve a similar radiomigitation effect in rhesus monkey, doses that are pharmacologically equivalent to those given to mice should be administered to rhesus monkeys. Based on the Food and Drug Administration (FDA) guidelines [28] , the optimal 20 ng/mouse dose (1000 ng/Kg) and a non-optimal 80 ng/mouse (4000 ng/Kg) dose in mouse translate, respectively, to the 250 ng/Kg and 1000 ng/Kg doses in rhesus monkey. However, eliciting a pharmacologically equivalent response at species-specific equivalent doses depends on several factors including similar drug exposure and specific reactivity with the primary target site in both species. Therefore, prior to evaluating the efficacy of the radiomitigation effects of HemaMax in NHP, we first examined the pharmacological equivalency of the speciesspecific equivalent doses. 
Plasma PK of HemaMax in Rhesus Monkeys
Plasma PK of HemaMax was examined in rhesus monkeys following a single administration of HemaMax at two doses of 250 ng/Kg and 1000 ng/Kg in the absence of irradiation. Following administration, the exposure (AUC last ) to HemaMax increased in proportion to dose ( Table 2 ). The AUC last of HemaMax in rhesus monkey was perfectly superimposed linearly for the AUC last of m-HemaMax in mice over the dose range of 10 ng/mouse to 80 ng/mouse (Figure 8) , suggesting that the species-specific equivalent doses calculated from mice studies provided similar drug exposure in monkeys. The 200 ng/mouse dose was not included in this analysis as it appeared that mHemaMax exhibits different PK characteristics at higher doses (Table 1) .
HemaMax at a single dose of 250 ng/Kg or 1000 ng/Kg was well tolerated and was not associated with overt signs of toxicity, except for the occurrences of transient decreases in appetite in the 1000 ng/Kg group.
HemaMax Administration Increased Plasma Concentrations of IFN-c, IL-15, IL-18, Neopterin, and EPO In Non-Irradiated Rhesus Monkeys
In monkeys, subcutaneous administration of HemaMax appeared in plasma shortly after administration and was not detectable after 72 hours (Figure 9a) . Moreover, as observed in mice with m-HemaMax, HemaMax was observed to increase plasma IFN-c concentration in proportion to dose (Figure 9a ). Temporal kinetics of IFN-c response in rhesus monkey was, however, different from mouse in that the IFN-c response was delayed for a longer period of time and was much higher in magnitude (Figure 9a ). Neither HemaMax, nor IFN-c, was detected in plasma of monkeys that did not receive HemaMax.
Of other potential biomarkers, the exposure (AUC last ) to IL-18 and EPO was increased by 2.4-fold and 5.1-fold, respectively, as the HemaMax dose was increased from 250 ng/Kg to 1000 ng/ Kg (Figure 9b ). HemaMax also increased plasma IL-15 and neopterin concentrations, peaking at 72 hours and 96 hours, respectively, post HemaMax administration (Figure 9c) . In contrast to previous reports in humans [34] [35] [36] [37] , the plasma concentrations of rhesus monkey TNF-a and IL-10 were not changed. Numerous other potential biomarkers were screened, but were found to be below the limit of quantification.
NHP and Human Bone Marrow and Small Intestine Express IL-12Rb2
The expression of IL-12Rb2 in non-irradiated NHP (rhesus monkeys) and human femoral bone marrow and jejunum/ileum was evaluated by immunohistochemistry. As depicted in Figure 10a , NHP, as well as human, progenitor cells and megakaryocytes expressed IL-12Rb2. The expression of IL12Rb2 was also found on osteoblasts/osteoclasts from the bone marrow. However, it could not be determined as to whether these cells were osteoblasts and/or osteoclasts because the donated tissues were smears and did not include periosteum or other bone tissues. Bone marrow adipocytes were not stained positive for IL12Rb2.
In the small intestine, IL-12Rb2 was most commonly expressed in crypts (Figure 10b) . It is not known if IL-12Rb2-expression in the intestinal crypt is localized to Paneth cells, multipotent stem cells, or both. IL-12Rb2 expression was also noted in lymphoid cells populating the lamina propria and submucosal regions (Figure 10b ). Mucin secreting goblet cells did not express IL12Rb2. Both crypt and lamina propria IL-12Rb2-expressing cells could represent multifunctional mesenchymal-origin myofibroblasts that can serve as crypt shape-forming cells that also occupy both a stem cell niche and act as non-professional antigen presenting cells to immunomodulatory cells in the lamina propria. Further studies will establish the cellular and functional identity of IL-12Rb2-expressing cells in intestinal crypts and their supportive role in intestinal regeneration after radiation exposure.
HemaMax Administration Increased Survival in Irradiated, Unsupported Rhesus Monkeys
In a pilot study of 40 animals, the percent survival of rhesus monkeys exposed to an LD 50/30 of TBI ( 6.7 Gy) was determined following treatment with 100 ng/Kg or 250 ng/Kg of HemaMax administered at 24 hours or at 24 hours and 7 days post TBI. This study was conducted in the absence of any supportive care, including antibiotics. The doses of HemaMax were chosen based on PK/PD studies in rhesus monkeys and were equivalent to mHemaMax doses of 8 ng/mouse and 20 ng/mouse, respectively. As is depicted in Figure 11a , HemaMax at both doses, following either single or two administrations, migitated death due to irradiation to the same extent. Overall percentages of survival were 71% in the 100 ng/Kg single dose group (n = 7) and 75% in all other groups receiving HemaMax (n = 8) compared to 50% in the vehicle group. Between-group differences in percentage of survival were not statistically significant, most likely because of the small number of animals in each group (n = 8), but also because both HemaMax doses were likely within the efficacious dose range. However, analysis of the percent survival regardless of the HemaMax dosing regimen indicated that when pooled together, monkeys treated with HemaMax had significantly higher percent survival than those receiving vehicle (75% vs 50%, respectively; P = .05) (Figure 11b ).
Changes in Blood Cell Counts of Irradiated, Unsupported Rhesus Monkeys Following HemaMax Administration
Three analyses were conducted to assess differences in blood cell counts during the study period. In the first analysis, where blood cell counts were analyzed from day 1 up to day 30, animals treated with HemaMax had significantly higher numbers of leukocytes and thrombocytes at days 12 and 14, around the nadir, for the 100 ng/Kg and 250 ng/Kg doses, as compared to animals treated with vehicle ( Figure 12) .
In a second analysis, where blood cell counts were analyzed from day 1 up to day 14, the day before any animals died, animals treated with HemaMax had higher platelets counts compared to animals treated with vehicle (P = .079 for the 250 ng/Kg group and P = .02 for the 100 ng/Kg twice dosing group) during nadir (days 12 to 14). Additionally, in comparison to the vehicle group, animals treated with HemaMax had significantly higher counts of leukocytes (P,.01 for the 250 ng/Kg group and P,.04 for the 100 ng/Kg twice dosing group) and reticulocytes (P,.04 for the 250 ng/Kg group and P,.001 for the 100 ng/Kg group) during nadir (days 12 to 14). The same trend was apparent for neutrophil, basophil, and lymphocyte counts, but they did not reach acceptable levels of statistical significance.
In a third analysis the number of animals that reached clinically low platelet counts during the study was assessed. This analysis revealed a remarkable difference between the vehicle and HemaMax groups in the number of platelet counts dropping below a threshold level of 20,000 platelets/mL, a level generally necessitating platelet transfusion. In the HemaMax 250 ng/Kg group, only 4 out of 16 (25%) platelet counts at the nadir (day 12 to day14) dropped below the transfusion threshold of less than 20,000 platelets/mL whereas 12 out of 15 (80%) platelet counts for the vehicle animals were below the threshold level during the same period of time (P = .007).
Taken altogether, these findings indicate that HemaMax increases leukocytes, platelet, and reticulocyte counts just prior to the days on which animals begin to die from radiation toxicity (day 13, Figure 11a) . Interestingly, vehicle-treated animals that survived up to day 30 also had quick recovery of blood cell counts, which were statistically indistinguishable from those in the HemaMax groups. These findings suggest that mortality likely occurs in animals that do not show a strong blood cell recovery around the nadir day(s). The validity of this hypothesis was evaluated by comparing blood cell counts of animals stratified by the mortality status, i.e., those surviving up to day 30 versus animals dying after day 12. In this analysis, the blood cell counts on the day before death was taken for animals that died after day 12. The comparison day for the surviving animals in each group was the average day on which the decedents in a particular group died (days 14 to 18). This analysis demonstrated that, regardless of the particular treatment group, animals surviving up to day 30 had significantly higher counts of platelets, neutrophils, leukocytes, reticulocytes, and lymphocytes than those that died after day 12 (P,.001 to P,.05). When compared by treatment group, animals treated with 100 ng/Kg HemaMax had significantly higher counts of neutrophils, leukocytes, and lymphocytes than did those treated with vehicle in both survivors and decedent groups (P,.001 for all three cell types). In addition, animals treated with 100 ng/Kg HemaMax had a numerically higher platelet and reticulocyte counts. These findings suggest that HemaMax-induced increase in blood cell counts around nadir may play a key role in promoting survival following radiation exposure.
Clinical and Physical Characteristics of Irradiated, Unsupported Rhesus Monkeys Following HemaMax Administration
Animals receiving HemaMax at the dose of 100 ng/Kg (once or twice) had consistently higher mean body weights than did those in the vehicle group from days 14 to day 30 ( Figure 13a ). Animals treated with HemaMax at the dose of 100 ng/Kg (once or twice) or 250 ng/Kg (once) had less weight loss than did animals treated with vehicle from days 14 to 30 ( Figure 13 c and d) . Although the between group differences in body weight or weight loss were not statistically significant, when the analysis of body weight loss was limited to day 12-the approximate day for blood cell nadir and the day after which animals began to die (Figure 11a )-the pooled HemaMax-treated animals had significantly less body weight loss were not significantly different from the vehicle group, although appetite and physical activity improved in HemaMax treated animals, and the incidence of diarrhea and black or red feces declined in the 250 ng/Kg twice dosing regimen group. However, above-mentioned clinical signs did predict mortality after day 12 by logistic regression (P = .002 for decreased appetite, P,.001 for decreased physical activity, P = .04 for incidence of diarrhea, and P = .008 for incidence of red or black feces). Clinical signs of severe deterioration and stress, including chronic anorexia, sunken eyes, dehydration, hunched and/or crouching posture and weakness, started approximately at day 14 with no remarkable betweengroup differences in the incidence or onset. All adverse clinical signs were consistent with acute radiation syndrome following exposure to radiation. Gross pathology along with organ and hemoculture bacteriology evaluation was conducted for all animals, which died or were euthanized before the end of study. There were no HemaMaxrelated macroscopic lesions. The incidence of hemorrhage was 12.5% (1/8 animals) in the pooled animals treated with 100 ng/ Kg or 250 ng/Kg of HemaMax compared to 50% (2/4) in the vehicle animals. In the vehicle group, all of the decedent animals (4/8 animals) were found dead while only 1 animal in the HemaMax groups was found dead and 8 animals were humanely euthanized before the end of study. A diagnosis of septicemia was confirmed by isolation of the same bacterial strain in at least 2 organs of all 13 animals.
In the vehicle group, 75% (3/4) found dead animals presented a combination of bacteria most likely from the intestinal and cutaneous flora and 25% (1/4) presented organ infections with only bacteria most likely from the cutaneous bacterial flora. In the various HemaMax-treated groups, 8 out of 9 animals (89%) presented a combination of bacteria from the intestinal and cutaneous flora, including 2 which also presented organ infections with bacteria most likely from the environment. The other animal (1/9) presented organ infections with only bacteria most likely from the cutaneous flora. These results suggest that opportunistic infections were present in all animals that died preterminally in this animal model of acute radiation syndrome.
Discussion
Radiation toxicity caused by TBI dose-dependently implicates immune, hematopoietic and the GI tissues, as these are the most radiosensitive targets in the body. Lymphocytes are the most sensitive cells to radiation toxicity and, at irradiation doses of .2 Gy, are the first to be depleted from circulation. The lymphocyte loss is followed by a decline in granulocytes and then platelet levels over a period of days. Acute-onset anemia may occur secondary to hemorrhage [1, 2] . At doses of .4 Gy, radiation adversely affects GI epithelium/endothelium, and the resulting clinical manifestation is due to a combination of the hematopoietic and GI toxicities, presenting with nausea, vomiting, diarrhea, headache, fatigue, fever, and abdominal pain [1, 2] . Death originating from immune and hematopoietic toxicity occurs because of infection due to impaired immunity and/or hemorrhage due to thrombocytopenia, while death originating from GI toxicity is often because of multisystem organ failure, overwhelming sepsis, and complications of bleeding [2] . In the event of a radiological attack, radiation mitigators with multi-tissue effects capable of alleviating immune, hematopoietic and GI toxicities when administered after radiation exposure, are needed to save lives.
Our findings demonstrate that HemaMax (this term is used throughout this discussion to collectively include its prototype mHemaMax as well) mitigated death due to radiation-induced toxicity in both mice and monkeys following administration of a single, low dose. Importantly, in both mice and monkeys, HemaMax increased survival when administered at protracted timepoints post radiation exposure, such as 24 hours or longer, in the absence of supportive care, including oral or topical antibiotics. In irradiated mice and monkeys, HemaMax promoted survival at various levels by stimulating the immune system in the peripheral blood and extravascular spaces, promoting hematopoietic regeneration in bone marrow, decreasing tissue injury in the small intestine, and triggering a generalized anti-apoptotic and anti-inflammatory effect throughout the body.
The optimal murine dose that provided these radiomitigation effects is approximately 20 ng/mouse. This dose is ostensibly lower than our previous reports for HemaMax efficacy in radioprotection and as a hematological adjuvant in cancer therapy [13, 14] . However, the discrepancy is likely due to the use of formulated protein in the present studies. Moreover, protracted administration of HemaMax at 24 hours post irradiation appears to act via a somewhat different mechanism as compared with our previous studies where HemaMax was administered either before, or shortly after, radiation exposure [13, 14] . Evidence for this statement comes from a comparison of the bone marrow recovery in the current murine radiomitigation studies, as compared to previous studies in mice [14, 38] . In the current studies, bone marrow recovery appeared to be much slower, likely due to the timing of HemaMax administration (24 hours before TBI in previous studies versus 24 hours after TBI in this study).
Further, in the current radiomitigation studies in mice, when compared to irradiated control, HemaMax markedly decreased the radiation induced expression of LRG5, a stem cell marker which also serves as a marker of GI injury, when administered at 24 hours post radiation exposure. HemaMax, at doses from 10 ng/mouse to 40 ng/mouse administered 24 hours post TBI, reduced radiation-induced LGR5 expression. In contrast, with 200 ng/mouse HemaMax administration 24 hours after TBI, appeared to exacerbate radiation-induced GI injury as evidenced by an increase in LGR5 expression.. This finding may be consistent with earlier reports that high doses of IL-12 exacerbated radiation injury to the GI tract [14, 38] . Data obtained in both mice (data not shown) and rhesus monkeys show significant increases in body weights for m-HemaMax and HemaMax-treated animals, respectively,after irradiation (Figure 13 ), thereby providing further support for the protective GI effect of of HemaMax treatment.
Our findings that HemaMax can reduce radiation toxicity and increase survival in mice was confirmed in monkeys. HemaMax administered to rhesus monkeys at 24 hours post radiation significantly increased survival (P = .05, pooled treated groups vs. vehicle control). HemaMax-treated monkeys had significantly higher numbers of platelets, leukocytes, and reticulocytes at the nadir, had lower incidence of hemorrhage, and had higher body weights from day 12 to day 30.
To provide perspective about the importance of body weight changes, it is worth mentioning that weight loss after day 12 is a strong predictor of survival (P,.001). The lack of statistically significant between-group differences in the incidence of cause of death from hemorrhage and decreases in body weight is likely because of the small number of animals in each group. On the other hand, if the change in body weight analysis was limited to the blood cell nadir (day 12), just before animals began dying, the pooled group analysis (all HemaMax-treated groups versus the vehicle group) resulted in a statistically significant difference (P = .04), while the individual HemaMax-treated groups were marginally different from the vehicle group (P = .078). Moreover, thrombocytopenia was less severe in animals treated with HemaMax than in those treated with vehicle. Further, a remarkable difference was observed between the vehicle and HemaMax-treated groups in platelet counts dropping below the threshold level of 20,000 platelets/mL, a level that generally necessitates platelet transfusion. In the HemaMax-treated 250 ng/ Kg group, only 4 out of 16 (25%) platelet counts at the nadir (day 12 to day14) dropped below the transfusion threshold of less than 20,000 platelets/mL whereas 12 out of 15 (80%) platelet counts for the vehicle animals were below the threshold during the same period of time (P = .007). Thus, in spite of small number of animals in the monkey study, statistically significant differences were observed in several key survival-related parameters. These findings are significant as, in our study, HemaMax was administered after TBI, the earliest at 24 hours post irradiation-a window of time considered minimally necessary for mobilization of medical personnel and resources to the affected area. This is the first study that demonstrates the potential of HemaMax as a life-saving intervention in the event of a radiological disaster.
Our findings reported here provide evidence that when administered as single, low doses after TBI, HemaMax mitigates radiation-induced toxicity in at least three major systems affected by radiation: the immune system, the bone marrow compartment, and the GI tract. HemaMax protection of the GI tract,however, remains to be confirmed in GI focused experiments implemented at higher radiation levels. An additional event related to the HemaMax mitigation of radiation toxicity is the stimulation of anti-apoptotic/anti-inflammatory effects via release of EPO, a known general protector of tissue against cytotoxic damage via anti-apoptotic/anti-inflammatory mechanisms [74] .
Several interdependent networks may underlie the radiomitigation effect of HemaMax. It is known that IL-12 is a central regulator of cell-mediated immune responses and modulates the synthesis and secretion of several immune mediators [39, 40] . In cancer patients, intraperitoneal/intravenous/subcutaneous administration of IL-12 increased peritoneal/serum levels of IFN-c, TNF-a, IL-10, IL-8, VEGF, IP-10, and neopterin [34] [35] [36] [37] . In our study, HemaMax administration dose-dependently increased plasma IFN-c levels in both mice and monkeys. IFN-c orchestrates many distinct cellular programs through transcriptional control over large numbers of genes, resulting in heightened immune surveillance and immune system efficiency against infection [41] . In addition to IFN-c, HemaMax increased plasma levels of EPO in mice (IL-15, IL-18 and neopterin were not tested) and IL-15, IL-18, neopterin, and EPO in monkeys. The lack of dose proportional response with IL-15, IL-18 and neopterin is likely due to saturation of target sites related to release of these mediators. However, the lack of a dose proportional response for EPO appears to be more related to an interplay between IFN-c and EPO, as suggested by our data and the reports of others [42, 43] . In a previous report, administration of EPO has been shown to suppress the inflammatory response related to IFN-c in an animal model of multiple sclerosis [29] .
IL-15 and IL-18, alone and/or in combination, play important roles in the development, homeostasis, and functions of CD4+ T cells, CD8+ T cells, natural killer (NK) cells, and NK T cells [44] [45] [46] . In synergism with IL-12, IL-18 stimulates the production of IFN-c in T helper 1 cells [47] . Neopterin, an auto-oxidation product of 7,8-dihydroneopterin, reflects IFN-c activity and, as a corollary, is considered as an indicator of systemic immune activation [48, 49] .
The current study is the first to demonstrate that HemaMax stimulates EPO production in mice and NHP. This finding suggests that EPO may play a central role in mediating the radiomitigation activity of HemaMax. The role of EPO in biological functions other than erythropoiesis has only recently begun to unravel, primarily after finding EPO receptors on cells other than erythroid progenitors, such as polymorphonuclear leukocytes, megakaryocytes, and endothelial, myocardial, and neuronal cells [50] [51] [52] [53] [54] [55] . Accumulating evidence indicates that EPO has immunomodulatory, neuroprotective, and cardioprotective activities. EPO enhances cell viability, modulates surface antigen expression, and increases IL-12 secretion in dendritic cells-the most potent antigen presenting cells-suggesting that immunomodulatory functions of EPO may partly be mediated through dendritic cells, which in turn induce specific T cell responses [56, 57] . Cytoprotective effects of EPO have at least in part, been linked to its antioxidant, anti-inflammatory and antiapoptotic activities. In various models of cytotoxicity induced by toxicants, ischemia, hypoxia, or oxidative stress, EPO increased cellular antioxidant capacity and/or decreased oxidant injury in kidney, neurons, and retinal pigment epithelial cells [58] [59] [60] [61] [62] while it reduced apoptosis in neurons, vascular smooth muscle cells, cardiomyocytes, and endothelial cells [63] [64] [65] [66] .
The underlying mechanisms of radiomitigation conferred by exogenous HemaMax is now beginning to be revealed by the findings of our current and previous studies, suggesting a multilevel response orchestrated by exogenous delivery of HemaMax ( Figure 14 GI stem cells (Level 3), and likely (d) on kidney cells (Level 4), whereby EPO, a cytoprotective factor, is released following radiation exposure (Figure 14) .
The most immediate response is the HemaMax-induced Level 1 Response, which involves key radioresistant cells of the immune system. At the very early stages following radiation exposure, most immune cells undergo apoptosis with a rank order according to their radiosensitivity (B cells.T regulatory cells.T helper cells.T cytotoxic cells.T memory cells.NK cells) [4] . The immune cells that are likely to remain functional at 24 hours or longer post irradiation are those that are the least radiosensitive, namely NK cells and differentiated cells, such as macrophages and dendritic cells. Thus, HemaMax administered after radiation can initiate the Level 1 response by promoting the proliferation and activation of the surviving NK cells, macrophages, and dendritic cells [4, 15] . The tridirectional cross-talk between NK cells, macrophages and dendritic cells further promotes their maturation and expansion via cytokines identified as biomarkers of the restoration of innate immunity, namely IFN-c, IL-15, IL-18 and neopterin [49, [67] [68] [69] . This tridirectional cross-talk further leads to the production of endogenous IL-12 secreted from dendritic cells ( Figure 14) . As a consequence, early immune competence is established via innate immunity mechanisms following TBI. Continuous production of endogenous IL-12 from pathogen-activated dendritic cells also serves as a positive feedback loop and plays a key role in sustaining the initial response to exogenous HemaMax, perhaps for weeks after radiation exposure (Figure 14) . Evidence for the continued production of endogenous IL-12 following exogenous administration of HemaMax is the presence of IL-12Rb2 on hematopoietic cells 12 days after TBI only in mice that were treated with HemaMax.
HemaMax initiates the Level 2 Response through interaction with the primary bone marrow cells involved in hematopoiesis. In the bone marrow, residual hematopoietic stem cells, osteoblasts, and megakaryocytes are likely the cell types that remain extant and functional 24 hours following exposure to lethal doses of radiation [70] . The presence of IL-12Rb2-expressing stem/ progenitor cells, megakaryocytes, and/or osteoblasts in bone marrow from mice, NHP, and humans indicates that these cells are direct targets of HemaMax. Through its receptors, HemaMax initiates the Level 2 response by promoting proliferation and differentiation of the surviving stem cells following radiation exposure, leading to hematopoietic regeneration ( Figure 14) . Activation of osteoblasts appears to be crucial for the survival, expansion, and homing of hematopoietic stem cells and megakaryocytes [70] [71] [72] [73] [74] [75] . It has been shown that exposure to lethal doses of radiation leads to a specific expansion of osteoblastic niche, whereby the surviving pool of radioresistant osteoprogenitors proliferates close to the endosteal bone areas [76] . The relatively long-lived, surviving megakaryocytes were also observed close to the endosteal surface of trabecular bone rather than in their normal parasinusoidal site. Megakaryocytes release factors that stimulated the expansion of osteoblastic niche [76] . Consistent with these findings, immunohistochemical examinations in our study revealed a similar cellular configuration in mice bone marrow, showing cellular islands consisting of osteoblastic niche, megakaryocytes, and hematopoietic stem cells close to the bone. In CD34+, IL-12Rb2-positive bone marrow cells, HemaMax increases EPO secretion while, in contrast to its traditional action in mature lymphocytes, it decreases IFN-c secretion [unpublished data from our lab], providing a milieu that promotes expansion of hematopoietic stem cells, eventually leading to regeneration of Figure 14 . A multilevel model of HemaMax mechanism of action in increasing survival following exposure to radiation. Current evidence suggests that HemaMax triggers responses at, at least, 4 levels in the body. At the Level 1 response, HemaMax promotes proliferation and activation of extant, radiosensitive immune cells, namely NK cells, macrophages, and dendritic cells. HemaMax-induced plasma elevations of IL-15 and IL-18 also facilitate maturation of NK cells, leading to the release of IFN-c, which in turn, positively affects the production of endogenous IL-12 from macrophages and dendritic cells, and perhaps NK cells. These events enhance the innate immune competency early on following HemaMax administration. At the Level 2 response, HemaMax promotes proliferation and differentiation of the surviving hematopoietic stem cells, osteoblasts, and megakaryocytes into a specific cellular configuration that ensues optimal hematopoiesis. HemaMax-induced secretion of EPO from CD34+, IL12Rb2-positive bone marrow cells may also suppress local over-production of IFN-c in the bone marrow and, thus, provide a milieu that promotes expansion of hematopoietic cells. Hematopoietic regeneration in the bone marrow enhances both innate and adaptive immune competency. At the Level 3 response, HemaMax preserves GI stem cells, leading to a reduction in pathogen leakage, an increase in food consumption, and a decrease in diarrhea. At the Level 4 response, HemaMax likely directly increases renal release of EPO, a cytoprotective factor, which enhances cellular viability in a diverse set of organs/tissues. Continued production of endogenous IL-12 primarily from dendritic cells activated by pathogens and/or EPO serves as a positive feedback loop and plays a key role in sustaining the initial response to exogenous HemaMax, perhaps for weeks after radiation. q = increase; Q = decrease; HSC = Hematopoietic stem cells; NK cells = natural killer cells. doi:10.1371/journal.pone.0030434.g014 mature blood cells including platelets and leukocytes (Figure 14) . EPO also contributes to the development of such optimal milieu by suppressing the over-production of inflammatory cytokines such as IFN-c, IL-6, IL-2, and TNF-a from T cells [29] . Inhibition of IFN-c production by EPO is in agreement with our findings showing that plasma IFN-c levels were suppressed in irradiated mice at a HemaMax dose (20 ng/mouse) that substantially increased plasma EPO levels. Furthermore, the increased plasma EPO concentrations may, at least in part, explain the lack of increases in monkey plasma levels of proinflammatory cytokines such as IL-2, IL-6, and TNF-a following HemaMax administration.
HemaMax initiates the Level 3 Response by preserving GI stem cells, which regenerate intestinal crypt cells and ensure intestinal integrity (Figure 14) . HemaMax-induces intestinal cell-cell border integrity, which reduces pathogen leakage, increases food absorption, and decreases diarrhea. The reduction of ''leaky gut syndrome'' provides further immune-related benefit by decreasing pathogen entry into peripheral blood circulation (Figure 14) . HemaMax-induced GI recovery thus provides a greater chance of survival following lethal radiation exposure.
HemaMax initiates the Level 4 Response by increasing plasma levels of EPO, likely by enhancing EPO release from the kidneys following direct activation of its renal receptors. Given its antioxidant, anti-inflammatory, and antiapoptotic activities, EPO acts as a general cytoprotective factor in the body, enhancing cellular viability in a diverse set of organs/tissues including the brain, peripheral nerves, heart, kidney, skin, and intestine [77] . EPO may also preserve key cells involved in Level 1 and 2 survival advantages of HemaMax, namely niche bone marrow cells, as well as mature and immature dendritic cells, macrophages, and NK cells against radiation toxicity. Matured dendritic cells may also release IL-12 in response to EPO [56, 57] and/or IFN-c [78] , providing a positive feedback loop that amplifies the events originally initiated by exogenous administration of HemaMax.
Finally, continuous generation of endogenous IL-12 induced by a single dose of exogenous HemaMax in irradiated, immunocompromised hosts is another key survival advantage. Continuous endogenous production of IL-12 is primarily a result of the Level 1 HemaMax-induced response. In addition, bacterial and pathogenic products gaining access to the circulation following radiation injury can activate dendritic cells to promote innate and adaptive responses, and further lead to a release of endogenous IL-12. Thus, we hypothesize that HemaMax promotes proliferation of surviving immune cells, cells of the bone marrow niche, namely osteoblasts and megakaryocytes, hematopoietic stem cells, and provides protection against radiation injury to key intestinal stem cells through various feedback loops. These feedback loops promote the generation of soluble factors such as endogenous IL-12, IFN-c, and EPO, allowing regeneration of hematopoietic system and recovery of immune and GI functions (Figure 14) .
The studies reported here culminate with the important finding from several proof of concept studies, where we demonstrate for the first time that HemaMax mitigates radiation-induced injury in NHP, an animal model that is closely related to human. Importantly, for the FDA Animal Rule path to approval, allometric dose conversion from mice to rhesus monkey allowed identification of comparable doses that provided similar HemaMax exposure in monkeys. Despite similar PK characteristics, the IFN-c response to HemaMax appeared to be stronger in monkeys compared to mice. The fact that the percentage of survival of rhesus monkeys was similar after receiving either a single dose or two doses of HemaMax at either 100 ng/Kg or 250 ng/Kg suggest that HemaMax is likely to be effective at even lower doses. Importantly, the HemaMax doses used in the NHP studies correspond to human doses of about 30 ng/Kg and 80 ng/Kg, respectively. In cancer patients, IL-12 has been administered intravenously, intraperitoneally, or subcutaneously at a dose range of 3 ng/Kg to 600 ng/Kg as a monotherapy or part of a combination therapy for the treatment of various carcinomas [34] [35] [36] 79, 80] . Intravenously, IL-12 has been associated with a high rate of toxicity [79] . Intraperitoneally, IL-12 reaches dose limiting toxicity (elevated transaminase) at 600 ng/Kg and is most frequently associated with fever, fatigue, abdominal pain, and nausea [80] . Subcutaneously, IL-12 is generally well tolerated when it is administered twice weekly at a range of 300 ng/Kg to 500 ng/Kg for up to 3 years [36] . In our studies, HemaMax was also well tolerated in monkeys after a single dose or up to seven doses of 1000 ng/Kg (data not shown) with no overt sign of toxicity.
Our safety studies in monkeys, coupled with the very low effective dose in both mice and monkeys, indicate that the requisite HemaMax dose for radiomitigation will be substantially lower than the IL-12 doses previously used in cancer patients, thus suggesting a more favorable safety profile for HemaMax in radiation victims Given the expected safety profile for HemaMax, it is envisioned that the drug could be disseminated to all individuals in the vicinity of a radiological event, even in the absence of any knowledge of the actual level of radiation exposure. Currently, a First-in-Human (FIH) study in healthy volunteers is ongoing.
Although the roles of IL-12 in immunity and cancer were the subject of intensive study in several clinical trials, IL-12 was never approved as a drug for any indication. The reason for the lack of advancement of IL-12 to approval was its modest clinical activity and significant toxicity due to high and repeated dosing regimens [15, 81] . As shown in this study, potent radiomitigation effects in mice and NHP can be achieved using very low, nanogram per kilogram doses of HemaMax given merely once. The single, very low dose of HemaMax required for its radiomitigation effects underscores both its potency and its expected safety in humans.
In an era of the increased risk for radiological terrorism or accident, medical contingency plans and preparedness are crucial to saving lives. The major components of such plans are the detection of radiation exposure, rapid determination of the absorbed radiation doses, and availability of the validated radiation mitigators [82] . Doubtlessly, effective radiomitigators are the key to the preparedness success. Our findings indicate that HemaMax may serve as a novel intervention for use as a frontline treatment to mitigate death due to radiation injury. First-inHuman, phase I studies are ongoing to assess the safety and pharmacokinetic and pharmcodynamic profiles of HemaMax, along with further efficacy studies in animals. The culmination of these human and animal studies will allow a determination of the predictive efficacious dose of HemaMax in humans under the Animal Rule, where efficacy is determined in animal models and safety is determined in humans.
